TIL Therapy for Non-Small Cell Lung Cancer (NSCLC): Research Status & Challenges

Current Status: Investigational, Not Approved

While TIL therapy has received FDA approval for advanced melanoma (Amtagvi/lifileucel, February 2024), its use in non-small cell lung cancer (NSCLC) remains strictly investigational. This means:

• TIL therapy is not available as a standard treatment for NSCLC
• Access is limited to patients enrolled in registered clinical trials
• The safety and efficacy profile in NSCLC is still being established
• NSCLC presents unique challenges that make TIL therapy more complex than in melanoma

Why Is TIL Therapy Being Studied in NSCLC?

Despite the challenges, NSCLC is an important target for TIL therapy research for several reasons:

High Unmet Medical Need

NSCLC is the most common type of lung cancer and a leading cause of cancer death worldwide. Advanced or metastatic NSCLC that has progressed after standard treatments (chemotherapy, targeted therapy, immunotherapy) has limited treatment options. TIL therapy represents a potential new approach for these heavily pre-treated patients.

Immunogenic Potential

Some NSCLC tumors, particularly those with high mutational burden (often associated with smoking history), may be more "visible" to the immune system. This immunogenicity suggests that TILs may be able to recognize and attack NSCLC cells.

Tumor-Infiltrating Lymphocytes in NSCLC

Studies have shown that NSCLC tumors often contain tumor-infiltrating lymphocytes (TILs). The presence of these cells suggests that the immune system is attempting to fight the cancer, but may be suppressed or exhausted. TIL therapy aims to extract, expand, and reinfuse these cells to overcome this suppression.

Unique Challenges of TIL Therapy in NSCLC

TIL therapy in NSCLC faces several challenges that are less prominent in melanoma:

1. Tumor Biopsy Risks

Obtaining tumor tissue for TIL harvest can be more risky in NSCLC compared to melanoma:

• Lung biopsies carry risks of pneumothorax (collapsed lung), bleeding, and infection
• Deep-seated tumors may be difficult to access safely
• Patients with compromised lung function may not tolerate biopsy procedures

2. Pulmonary Function Requirements

TIL therapy requires patients to have adequate lung function to tolerate:

• The biopsy procedure itself
• Potential pulmonary toxicity from IL-2 (capillary leak syndrome can affect lungs)
• The overall physiological stress of treatment

Many NSCLC patients have reduced lung function due to smoking history, COPD, or the cancer itself, which may limit eligibility.

3. Immunosuppressive Tumor Microenvironment

NSCLC tumors often develop mechanisms to suppress the immune system, making it more difficult for TILs to function effectively. This may result in lower response rates compared to melanoma.

4. Comorbidities

NSCLC patients often have multiple comorbidities (cardiovascular disease, COPD, diabetes) that may complicate TIL therapy or limit eligibility.

Active Clinical Trials in NSCLC

Several clinical trials are evaluating TIL therapy in NSCLC, with the most notable being the registrational program by Iovance Biotherapeutics:

IOV-LUN-202 (Iovance Biotherapeutics)

IOV-LUN-202 is a Phase 2 registrational trial evaluating Iovance's TIL therapy product in patients with advanced NSCLC who have progressed after prior anti-PD-1 therapy. Key features include:

• Trial Design: Phase 2 registrational study in patients with metastatic NSCLC previously treated with anti-PD-1/PD-L1 therapy
• Primary Endpoint: Objective response rate (ORR)
• Status: Actively enrolling; final efficacy and safety data are not yet available

Other Early-Phase Trials

Beyond IOV-LUN-202, additional early-phase studies are exploring TIL therapy in NSCLC, including:

• Combination approaches with checkpoint inhibitors
• Trials in earlier lines of therapy
• Studies exploring biomarkers to predict response

Preliminary Data

Early data from NSCLC TIL trials suggests:

• TIL therapy is feasible in selected NSCLC patients
• Objective responses have been observed in some patients, though response rates may be lower than in melanoma
• The safety profile is generally consistent with TIL therapy in other cancers, though pulmonary complications require careful monitoring

Key Differences: NSCLC vs. Approved Melanoma Indication

Understanding the differences between TIL therapy in NSCLC (investigational) and melanoma (approved) is critical for setting realistic expectations:

Aspect	NSCLC Investigational	Melanoma Approved
Regulatory Status	Not FDA-approved; clinical trials only	FDA-approved (Amtagvi, Feb 2024)
Key Trial	IOV-LUN-202 (Phase 2 registrational, enrolling)	C-144-01 (Phase 2, FDA-reviewed)
Tumor Biopsy Risk	Higher (lung biopsy risks)	Lower (skin/soft tissue biopsy)
Pulmonary Function Requirement	Critical (lung function must be adequate)	Important but less restrictive
Patient Comorbidities	Often more complex (COPD, cardiovascular)	Generally fewer comorbidities
Response Rate	Unknown (trials ongoing)	~31% (C-144-01 trial)
Access	Very limited clinical trials	Commercially available at certified centers

Eligibility Considerations for NSCLC Trials

Clinical trials for TIL therapy in NSCLC have strict eligibility criteria, with special attention to lung function and comorbidities:

Disease Status

• Advanced or metastatic NSCLC (Stage III or IV)
• Progression after standard therapies (chemotherapy, targeted therapy, immunotherapy)
• Measurable disease on imaging

Pulmonary Function (Critical)

• Adequate lung function (as assessed by the treating center based on pulmonary function tests)
• No severe COPD or emphysema
• No recent pulmonary complications (e.g., severe pneumonia)

Tumor Accessibility

• At least one tumor lesion that can be safely biopsied
• Lesion must be accessible via bronchoscopy, CT-guided biopsy, or surgical resection
• Adequate tissue yield expected for TIL extraction

Comorbidities

• No uncontrolled cardiovascular disease
• No severe renal or hepatic impairment
• No active autoimmune diseases

Performance Status

• ECOG performance status 0-1 (generally required)
• Able to tolerate the physiological stress of treatment

Treatment Process in NSCLC Trials

The TIL therapy process in NSCLC trials is similar to melanoma, with additional considerations for lung function:

1. Screening & Pulmonary Testing: Comprehensive evaluation including pulmonary function tests (PFTs), imaging, and assessment of comorbidities
2. Tumor Biopsy: CT-guided biopsy, bronchoscopy, or surgical resection to obtain tumor tissue (higher risk than skin biopsy)
3. Manufacturing: TILs are isolated and expanded (typically 4-6 weeks)
4. Lymphodepletion: Chemotherapy to suppress existing immune system
5. TIL Infusion: Intravenous infusion of expanded TILs
6. IL-2 Administration: High-dose IL-2 with intensive monitoring (special attention to pulmonary complications)
7. Follow-Up: Close monitoring for response, side effects, and pulmonary function

Side Effects: Special Considerations for NSCLC

The side effect profile of TIL therapy in NSCLC is expected to be similar to melanoma, with additional considerations:

• Lymphodepletion Effects: Low blood counts, infection risk, fatigue
• IL-2 Toxicity: Capillary leak syndrome (can affect lungs, causing pulmonary edema), low blood pressure
• Biopsy-Related Risks: Pneumothorax, bleeding, infection (specific to lung biopsy)
• Pulmonary Complications: Potential for worsening of underlying lung disease or new pulmonary toxicity

For detailed information on TIL therapy side effects, see our comprehensive side effects guide →

Unspoken Questions: What NSCLC Patients Really Want to Know

"Is TIL therapy worth the risk for NSCLC?"

This is a highly individual decision. TIL therapy offers potential benefits (novel mechanism of action, possible durable responses) but also carries significant risks, especially in NSCLC patients with compromised lung function. The decision should be made after thorough discussion with your oncologist, considering your specific situation, goals, and alternatives.

"What if my lung function is borderline?"

If your lung function is borderline, the trial team will carefully evaluate whether the potential benefits outweigh the risks. In some cases, patients may not be eligible for safety reasons. Your oncologist can discuss alternative treatment options if TIL therapy is not appropriate.

"Are there fewer clinical trials for NSCLC compared to melanoma?"

Yes. TIL therapy trials in NSCLC are more limited than in melanoma, partly due to the challenges mentioned above. This means fewer options for enrollment and potentially longer wait times. Your oncologist can help identify available trials and specialized centers.

"What if I have COPD or a smoking history?"

A history of smoking or COPD does not automatically exclude you from TIL therapy trials, but it does require careful evaluation of your current lung function. The trial team will assess whether your lung function is adequate to tolerate the treatment safely.

"What are my alternatives if I'm not eligible for TIL therapy?"

If you are not eligible for TIL therapy, your oncologist can discuss other options, which may include:

• Other immunotherapy approaches (checkpoint inhibitors, antibody-drug conjugates)
• Targeted therapies (if specific mutations are present)
• Clinical trials of other investigational treatments
• Palliative care to manage symptoms and improve quality of life

Global Access & Trial Availability

TIL therapy clinical trials for NSCLC are primarily being conducted in the United States and Europe, with limited availability in other regions. Key considerations include:

• Limited Trial Sites: Fewer centers are conducting NSCLC TIL trials compared to melanoma
• Travel Requirements: Patients may need to travel long distances to participate
• Specialized Expertise: Trials require centers with expertise in both TIL therapy and lung cancer management

What Records Will the Trial Team Need?

If you are interested in participating in a TIL therapy trial for NSCLC, the trial team will typically require:

• Pathology Reports: Confirmation of NSCLC diagnosis, including histology (adenocarcinoma, squamous cell, etc.) and molecular testing results (EGFR, ALK, PD-L1, etc.)
• Treatment History: Detailed records of all prior treatments, including dates, dosages, and response
• Pulmonary Function Tests (PFTs): Recent PFT results to assess lung function
• Imaging: Recent CT, PET/CT scans to assess current disease status
• Comorbidity Documentation: Records of other medical conditions (cardiovascular, COPD, etc.)

Questions to Ask Your Oncologist or Trial Team

1. Am I eligible for any TIL therapy clinical trials for NSCLC, including IOV-LUN-202?
2. What are the specific risks of TIL therapy for someone with my lung function and medical history?
3. How does the tumor biopsy procedure work for lung cancer, and what are the risks?
4. What are the potential benefits and risks compared to other treatment options?
5. What are the trial's specific eligibility criteria, and do I meet them?
6. What costs will be covered by the trial, and what will I be responsible for?
7. How will my lung function be monitored during and after treatment?
8. Are there alternative treatments or clinical trials I should consider?

Related Resources

Frequently Asked Questions